USA – Systemic Treatment Pathway Recurrent GBM Patients
[vc_row][vc_column][vc_custom_heading text="USA - Systemic Treatment Pathway Recurrent GBM Patients" font_container="tag:h2|text_align:center" use_theme_fonts="yes"][/vc_column][/vc_row][vc_row][vc_co ...
FDA Grants Orphan Drug Status to Beactica’s BEA-17 for Glioblastoma Treatment
Beactica Therapeutics, a Swedish precision oncology company, announced today that the U.S. FDA has designated BEA-17 as an orphan drug for the treatment of glioblastoma (GBM). BEA-17 is a first-of-its ...